Phase 3 Alzheimer's Disease Trial, Recruiting NCT05397639 Sponsor: Suven Life Sciences Limited Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 3 Alzheimer's Disease Trial, Recruiting

NCT05397639
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Alzheimer's disease dementia, confirmed using recognised medical guidelines.
  • You have been confirmed to have agitation (such as restlessness, irritability, or disruptive behaviour) related to your condition, assessed using a standard checklist.
  • Your memory and thinking abilities fall within a mild-to-moderate range, based on a standard test called the Mini-Mental State Examination (a score between 8 and 24 out of 30).

Who may not be able to join:

  • You have a type of dementia that is mainly caused by something other than Alzheimer's disease, such as vascular dementia, Parkinson's disease, Lewy body disease, or frontotemporal dementia.
  • Your agitation appears to be caused by something other than Alzheimer's disease, such as pain, another mental health condition, confusion caused by a medical condition, an infection, or a reaction to a substance.
  • The doctor running the trial, or the person caring for you, has determined for any other reason that you are not suitable to take part in this study (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +9140 2319 3956

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Suven Life Sciences Limited
Registry
ClinicalTrials.gov
Start date
1 November 2022
Est. completion
1 December 2026

Where this trial is recruiting

🇭🇷 Croatia 🇵🇱 Poland 🇷🇸 Serbia 🇺🇸 United States

Primary endpoints

Cohen-Mansfield Agitation Inventory (CMAI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov